XENE Crosses Above Average Analyst Target
October 05, 2021 at 09:13 AM EDT
In recent trading, shares of Xenon Pharmaceuticals Inc (XENE) have crossed above the average analyst 12-month target price of $27.17, changing hands for $31.60/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..